MedTrace Logo

Serum Neurofilament Light in Multiple Sclerosis

NCT06282081 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 42

Last updated 2025-02-14

No results posted yet for this study

Summary

This prospective cohort study is designed to characterize the utility of sNfL as a biomarker in clinical practice. This study also aims to understand how access to sNfL measures affects patient and clinician knowledge of their disease status and capture how this may have the potential to influence clinical decision-making. Level of disability, cognitive changes, fatigue, depression, and quality of life to detect clinical and subclinical worsening will be measured. While there is strong evidence in support of sNfL as a potential biomarker, literature regarding the application of sNfL in a real-world clinical practice setting is lacking. Understanding the utility of this test to clinicians and patients as a biomarker of MS disease activity is essential. Additionally, the optimum sampling frequency in clinical practice should be investigated to further elucidate its practicality. Given recent advances in the treatment of MS, there is increasing need for convenient and accessible measures of treatment efficacy.

Conditions

Interventions

DIAGNOSTIC_TEST

Serum Neurofilament Light

The purpose of this research is to investigate a biomarker, called serum neurofilament light (sNfL), which is measured in blood. This study will attempt to investigate whether or not sNfL is a useful tool for clinicians in patients diagnosed with relapsing remitting multiple sclerosis.

Sponsors & Collaborators

  • Genentech, Inc., a subsidiary of F. Hoffman-La Roche AG

    collaborator UNKNOWN

  • Monogram Biosciences (LabCorp Specialty Testing Group)

    collaborator UNKNOWN

  • Dent Neuroscience Research Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-09
Primary Completion
2026-03-01
Completion
2027-03-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06282081 on ClinicalTrials.gov